Kazuhiro Tanaka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kazuhiro Tanaka has a total of 254 co-authors. Here are the top co-authors by number of shared publications:
- Takashi Sasayama
Department of Neurosurgery, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
17 shared publications - Eiji Kohmura
Department of Neurosurgery, Kobe University Graduate School of Medicine
8 shared publications - Atsushi Fujita
Department of Neurosurgery, Kobe University Graduate School of Medicine, Kobe, Japan
7 shared publications - Kohkichi Hosoda
Department of Neurosurgery, Myodani Hospital, Kobe, Hyogo, Japan
7 shared publications - Masaaki Kohta
Department of Neurosurgery, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
7 shared publications Hiroaki Nagashima
Department of Neurosurgery, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan
6 shared publications
Latest Publications
- 7 October 2026
- Published by Wolters Kluwer Health in Stroke
Carbenoxolone Modulates Dopamine D2 Receptor–Associated Inflammatory Responses After Ischemic Stress
BACKGROUND: Despite advances in reperfusion therapy, ischemic brain injury remains a major cause of disability. Astrocytes play a central role in postischemic inflammation and tissue remodeling, but the molecular drivers of their reactive state transitions remain unclear. Here, we investigated whether carbenoxolone modulates reactive astrocyte phenotypes through astrocytic Drd2 signaling after cerebral ischemia. METHODS: In vivo rat cerebral ischemia–reperfusion model and in vitro oxygen-glucose deprivation/reperfusion paradigms were used. Infarct volume and neurological outcomes were assessed in vivo. Transcriptomic profiling was performed by RNA sequencing, followed by validation of representative genes using quantitative real-time polymerase chain reaction. Functional effects were evaluated in astrocytes and neuron-astrocyte coculture systems, and the involvement of Drd2 was examined using genetic knockdown approaches. RESULTS: Carbenoxolone reduced infarct volume and improved neurological outcomes both in the acute phase and 14 days after cerebral ischemia–reperfusion in rats. RNA sequencing revealed that carbenoxolone attenuated inflammatory signaling and reduced the expression of reactive astrocyte markers, including interleukin-1 beta and Cd44 . RNA sequencing identified Drd2 as a prominently upregulated gene in carbenoxolone-treated rats compared with saline controls. These transcriptional changes were validated at both the mRNA level by quantitative real-time polymerase chain reaction and the protein level by Western blotting. Functionally, under oxygen-glucose deprivation/reperfusion conditions, carbenoxolone enhanced cell survival in astrocytes and neuron–astrocyte cocultures, but not in neurons alone, indicating an astrocyte-mediated protective effect. Genetic silencing of Drd2 increased the reactive astrocyte marker Cd44 (cluster of differentiation 44) under basal conditions and partially attenuated carbenoxolone-induced cytoprotection after oxygen-glucose deprivation/reperfusion. CONCLUSIONS: Carbenoxolone modulates postischemic inflammatory responses and reactive astrocyte-associated programs, with evidence supporting a role for Drd2 signaling in these effects. These findings provide mechanistic insight into carbenoxolone-mediated neuroprotection and suggest Drd2 signaling as a potential therapeutic target in ischemic brain injury.
- 7 October 2026
- Published by Wolters Kluwer Health in Stroke
Carbenoxolone Modulates Dopamine D2 Receptor–Associated Inflammatory Responses After Ischemic Stress
BACKGROUND: Despite advances in reperfusion therapy, ischemic brain injury remains a major cause of disability. Astrocytes play a central role in postischemic inflammation and tissue remodeling, but the molecular drivers of their reactive state transitions remain unclear. Here, we investigated whether carbenoxolone modulates reactive astrocyte phenotypes through astrocytic Drd2 signaling after cerebral ischemia. METHODS: In vivo rat cerebral ischemia–reperfusion model and in vitro oxygen-glucose deprivation/reperfusion paradigms were used. Infarct volume and neurological outcomes were assessed in vivo. Transcriptomic profiling was performed by RNA sequencing, followed by validation of representative genes using quantitative real-time polymerase chain reaction. Functional effects were evaluated in astrocytes and neuron-astrocyte coculture systems, and the involvement of Drd2 was examined using genetic knockdown approaches. RESULTS: Carbenoxolone reduced infarct volume and improved neurological outcomes both in the acute phase and 14 days after cerebral ischemia–reperfusion in rats. RNA sequencing revealed that carbenoxolone attenuated inflammatory signaling and reduced the expression of reactive astrocyte markers, including interleukin-1 beta and Cd44 . RNA sequencing identified Drd2 as a prominently upregulated gene in carbenoxolone-treated rats compared with saline controls. These transcriptional changes were validated at both the mRNA level by quantitative real-time polymerase chain reaction and the protein level by Western blotting. Functionally, under oxygen-glucose deprivation/reperfusion conditions, carbenoxolone enhanced cell survival in astrocytes and neuron–astrocyte cocultures, but not in neurons alone, indicating an astrocyte-mediated protective effect. Genetic silencing of Drd2 increased the reactive astrocyte marker Cd44 (cluster of differentiation 44) under basal conditions and partially attenuated carbenoxolone-induced cytoprotection after oxygen-glucose deprivation/reperfusion. CONCLUSIONS: Carbenoxolone modulates postischemic inflammatory responses and reactive astrocyte-associated programs, with evidence supporting a role for Drd2 signaling in these effects. These findings provide mechanistic insight into carbenoxolone-mediated neuroprotection and suggest Drd2 signaling as a potential therapeutic target in ischemic brain injury.
- Open Access
- 4 June 2026
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 178 (2)
Long-term clinical outcomes and recurrence factors in intracranial germinoma
Intracranial germinomas have a favorable prognosis, but recurrence is not uncommon. Risk factors for recurrence and optimal long-term follow-up strategies remain undefined. This study assessed long-term outcomes and recurrence-related factors. Patients with intracranial germinomas treated at a single institution between 1984 and 2024 were retrospectively reviewed. Long-term overall survival (OS) and progression-free survival (PFS) were evaluated. Recurrence factors were analyzed by comparing the recurrence and non-recurrence groups. For patients receiving whole ventricular irradiation (WVI) or whole-brain radiation therapy (WBRT), irradiation plans were re-evaluated to determine whether the entire ventricular system was covered. Forty-three patients were included (median follow-up, 11.0 years). The 10-/15-year OS and PFS rates were 97.4%/81.8% and 86.1%/81.3%, respectively. Eight patients (18.6%) experienced disease recurrence. Univariate analysis showed that atypical tumor location and non-complete response after initial treatment were associated to higher recurrence risk, whereas radiation therapy (RT) including the entire ventricular system was associated with lower risk. Multivariate analysis showed that RT including the entire ventricular system reduced recurrence risk (hazard ratio 0.060; 95% CI 0.012–0.312; p < 0.001). Among the eight recurrence cases, three involved spinal recurrence after prolonged remission at 8.4, 17.5, and 18.1 years, respectively. RT including the entire ventricular system can prolong PFS. Among patients who underwent whole-ventricular RT using opposing portal radiation, some had insufficient radiation field coverage. Even after long-term remission, clinicians should review the initial RT field, and cases with insufficient ventricular irradiation should be monitored closely for recurrence risk. The online version contains supplementary material available at 10.1007/s11060-026-05665-6.
- 4 June 2026
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 178 (2)
Open AccessLong-term clinical outcomes and recurrence factors in intracranial germinoma
Intracranial germinomas have a favorable prognosis, but recurrence is not uncommon. Risk factors for recurrence and optimal long-term follow-up strategies remain undefined. This study assessed long-term outcomes and recurrence-related factors. Patients with intracranial germinomas treated at a single institution between 1984 and 2024 were retrospectively reviewed. Long-term overall survival (OS) and progression-free survival (PFS) were evaluated. Recurrence factors were analyzed by comparing the recurrence and non-recurrence groups. For patients receiving whole ventricular irradiation (WVI) or whole-brain radiation therapy (WBRT), irradiation plans were re-evaluated to determine whether the entire ventricular system was covered. Forty-three patients were included (median follow-up, 11.0 years). The 10-/15-year OS and PFS rates were 97.4%/81.8% and 86.1%/81.3%, respectively. Eight patients (18.6%) experienced disease recurrence. Univariate analysis showed that atypical tumor location and non-complete response after initial treatment were associated to higher recurrence risk, whereas radiation therapy (RT) including the entire ventricular system was associated with lower risk. Multivariate analysis showed that RT including the entire ventricular system reduced recurrence risk (hazard ratio 0.060; 95% CI 0.012–0.312; p < 0.001). Among the eight recurrence cases, three involved spinal recurrence after prolonged remission at 8.4, 17.5, and 18.1 years, respectively. RT including the entire ventricular system can prolong PFS. Among patients who underwent whole-ventricular RT using opposing portal radiation, some had insufficient radiation field coverage. Even after long-term remission, clinicians should review the initial RT field, and cases with insufficient ventricular irradiation should be monitored closely for recurrence risk. The online version contains supplementary material available at 10.1007/s11060-026-05665-6.
- Open Access
- 2 February 2026
- Published by Wolters Kluwer Health in Neurosurgery Practice
- Vol. 7 (1)
Trilaminar DuraGen-Anchored Closure for Dural Repair in Posterior Fossa Surgery: Technical Note and Case Series
BACKGROUND AND OBJECTIVES: Cerebrospinal fluid (CSF) leakage remains a common complication of posterior fossa surgery, often exacerbated by early postoperative mobilization. We describe a novel fibrin glue-free technique—trilaminar DuraGen-anchored closure—designed to enhance watertight dural sealing through circumferential suturing of DuraGen patches placed both subdurally and epidurally. METHODS: We retrospectively reviewed 20 patients who underwent posterior fossa surgery with this closure technique between 2020 and 2025. A subdural DuraGen patch approximately 1 cm larger than the dural defect was sutured circumferentially to the native dura. A second DuraGen layer was placed epidurally and similarly sutured. Although fibrin glue was used to seal exposed mastoid air cells, it was deliberately omitted from the duraplasty itself. CSF leak and wound-related complications were assessed clinically, although pseudomeningocele was evaluated radiologically using noncontrast computed tomography on postoperative day 1 and magnetic resonance imaging within 3 months. RESULTS: MRI follow-up was obtained in 18 of 20 patients (90%), with a mean interval of 20.6 months (median: 18.5 months; interquartile range: 16.1 months). The 2 patients without MRI underwent computed tomography and clinical follow-up, with no complications observed. No CSF leaks, pseudomeningoceles, or wound-related complications were identified. No reoperations or lumbar drainage were required. The technique was straightforward and reproducible across levels of surgical experience. CONCLUSION: The trilaminar DuraGen-anchored closure is a simple and effective fibrin glue-free method for achieving watertight dural closure in posterior fossa surgery. Its consistent performance supports further evaluation in broader clinical settings.
- 2 February 2026
- Published by Wolters Kluwer Health in Neurosurgery Practice
- Vol. 7 (1)
Open AccessTrilaminar DuraGen-Anchored Closure for Dural Repair in Posterior Fossa Surgery: Technical Note and Case Series
BACKGROUND AND OBJECTIVES: Cerebrospinal fluid (CSF) leakage remains a common complication of posterior fossa surgery, often exacerbated by early postoperative mobilization. We describe a novel fibrin glue-free technique—trilaminar DuraGen-anchored closure—designed to enhance watertight dural sealing through circumferential suturing of DuraGen patches placed both subdurally and epidurally. METHODS: We retrospectively reviewed 20 patients who underwent posterior fossa surgery with this closure technique between 2020 and 2025. A subdural DuraGen patch approximately 1 cm larger than the dural defect was sutured circumferentially to the native dura. A second DuraGen layer was placed epidurally and similarly sutured. Although fibrin glue was used to seal exposed mastoid air cells, it was deliberately omitted from the duraplasty itself. CSF leak and wound-related complications were assessed clinically, although pseudomeningocele was evaluated radiologically using noncontrast computed tomography on postoperative day 1 and magnetic resonance imaging within 3 months. RESULTS: MRI follow-up was obtained in 18 of 20 patients (90%), with a mean interval of 20.6 months (median: 18.5 months; interquartile range: 16.1 months). The 2 patients without MRI underwent computed tomography and clinical follow-up, with no complications observed. No CSF leaks, pseudomeningoceles, or wound-related complications were identified. No reoperations or lumbar drainage were required. The technique was straightforward and reproducible across levels of surgical experience. CONCLUSION: The trilaminar DuraGen-anchored closure is a simple and effective fibrin glue-free method for achieving watertight dural closure in posterior fossa surgery. Its consistent performance supports further evaluation in broader clinical settings.
- Open Access
- 12 January 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 8 (1)
Role of antiseizure medication in postoperative late seizure and survival among patients with newly diagnosed glioblastoma: A multicenter retrospective study
Background: We conducted a multicenter study to investigate the utility of postoperative antiseizure medication (ASM) in the occurrence of late seizure in glioblastoma. In addition, we analyzed whether postoperative ASM affects survival. Methods: 1132 consecutive patients with newly diagnosed glioblastoma at 39 centers were enrolled. In patients treated with postoperative ASM (levetiracetam [LEV], lacosamide [LCM], or perampanel [PER]), as well as in those who received no medication, the cumulative incidence of late seizure, adverse events, and survival outcomes were analyzed. Results: In total, 1099 patients (female: 482, male: 617, mean age: 67.2 years) were included, among whom, 287 developed postoperative late seizure. The mean onset time of late seizure was 193.6 days after surgery. Postoperative ASMs were administered in 628 cases, LEV in 344, LCM in 124, and PER in 160. The cumulative incidence of late seizure at 12 months was as follows: no medication in 30.9%, LEV in 17.8%, LCM in 28.8%, and PER in 16.2%. Multivariable analysis disclosed that LEV and PER displayed significantly lower cumulative incidences of postoperative late seizure compared with no medication and LCM. By contrast, median progression-free survival/overall survival did not significantly differ among ASMs. However, during the 12–24 month interval, the PER group demonstrated a more favorable prognosis than the other groups. Conclusions: LEV and PER after glioblastoma surgery were associated with a reduced risk of late seizure compared with LCM or no medication. LEV or PER may be considered as postoperative ASMs to optimize seizure control and potentially help preserve patients’ QOL.
- 12 January 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 8 (1)
Open AccessRole of antiseizure medication in postoperative late seizure and survival among patients with newly diagnosed glioblastoma: A multicenter retrospective study
Background: We conducted a multicenter study to investigate the utility of postoperative antiseizure medication (ASM) in the occurrence of late seizure in glioblastoma. In addition, we analyzed whether postoperative ASM affects survival. Methods: 1132 consecutive patients with newly diagnosed glioblastoma at 39 centers were enrolled. In patients treated with postoperative ASM (levetiracetam [LEV], lacosamide [LCM], or perampanel [PER]), as well as in those who received no medication, the cumulative incidence of late seizure, adverse events, and survival outcomes were analyzed. Results: In total, 1099 patients (female: 482, male: 617, mean age: 67.2 years) were included, among whom, 287 developed postoperative late seizure. The mean onset time of late seizure was 193.6 days after surgery. Postoperative ASMs were administered in 628 cases, LEV in 344, LCM in 124, and PER in 160. The cumulative incidence of late seizure at 12 months was as follows: no medication in 30.9%, LEV in 17.8%, LCM in 28.8%, and PER in 16.2%. Multivariable analysis disclosed that LEV and PER displayed significantly lower cumulative incidences of postoperative late seizure compared with no medication and LCM. By contrast, median progression-free survival/overall survival did not significantly differ among ASMs. However, during the 12–24 month interval, the PER group demonstrated a more favorable prognosis than the other groups. Conclusions: LEV and PER after glioblastoma surgery were associated with a reduced risk of late seizure compared with LCM or no medication. LEV or PER may be considered as postoperative ASMs to optimize seizure control and potentially help preserve patients’ QOL.
- Open Access
- 28 July 2025
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery: Case Lessons
- Vol. 10 (4)
Tumor-mimicking sarcoid-like reaction with lymphoid infiltration showing intracranial extension from the left jugular foramen: illustrative case
BACKGROUND: Accumulation of normal lymphocytes within the intradural extramedullary space is rare. To the best of the authors’ knowledge, no prior reports have described a sarcoid-like reaction with lymphoid infiltration arising around the jugular foramen and adhering to cranial nerves. Here, the authors present the case of a tumor-mimicking sarcoid-like reaction with intracranial extension from the left jugular foramen, adherent to the cerebellum, medulla oblongata, and lower cranial nerves. OBSERVATIONS: A 64-year-old woman with a history of serous otitis media and presumed tuberculous meningitis presented with persistent headache, left-sided tinnitus, hearing loss, hoarseness, and progressive vertigo. Imaging revealed a 2-cm enhancing mass around the left jugular foramen, extending intracranially and adhering to the cerebellum and medulla oblongata. The preoperative differential diagnoses included schwannoma, glomus tumor, meningioma, lymphoma, and granuloma. A retrosigmoid approach was used for biopsy and partial resection. Intraoperative pathology revealed lymphocytic infiltration without malignancy. Definitive pathology confirmed sarcoid-like lymphoid infiltration without evidence of neoplastic or infectious etiology. The patient showed a remarkable response to corticosteroid therapy, with both clinical and radiographic improvement and no recurrence at 20 months. LESSONS: Recognition of this rare entity and intraoperative identification of lymphocytic infiltration may support the use of corticosteroids and influence surgical decision-making. https://thejns.org/doi/10.3171/CASE25316
- 28 July 2025
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery: Case Lessons
- Vol. 10 (4)
Open AccessTumor-mimicking sarcoid-like reaction with lymphoid infiltration showing intracranial extension from the left jugular foramen: illustrative case
BACKGROUND: Accumulation of normal lymphocytes within the intradural extramedullary space is rare. To the best of the authors’ knowledge, no prior reports have described a sarcoid-like reaction with lymphoid infiltration arising around the jugular foramen and adhering to cranial nerves. Here, the authors present the case of a tumor-mimicking sarcoid-like reaction with intracranial extension from the left jugular foramen, adherent to the cerebellum, medulla oblongata, and lower cranial nerves. OBSERVATIONS: A 64-year-old woman with a history of serous otitis media and presumed tuberculous meningitis presented with persistent headache, left-sided tinnitus, hearing loss, hoarseness, and progressive vertigo. Imaging revealed a 2-cm enhancing mass around the left jugular foramen, extending intracranially and adhering to the cerebellum and medulla oblongata. The preoperative differential diagnoses included schwannoma, glomus tumor, meningioma, lymphoma, and granuloma. A retrosigmoid approach was used for biopsy and partial resection. Intraoperative pathology revealed lymphocytic infiltration without malignancy. Definitive pathology confirmed sarcoid-like lymphoid infiltration without evidence of neoplastic or infectious etiology. The patient showed a remarkable response to corticosteroid therapy, with both clinical and radiographic improvement and no recurrence at 20 months. LESSONS: Recognition of this rare entity and intraoperative identification of lymphocytic infiltration may support the use of corticosteroids and influence surgical decision-making. https://thejns.org/doi/10.3171/CASE25316
- Open Access
- 2 September 2024
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 54 (10) , 1123-1131
Cost of medical care for malignant brain tumors at hospitals in the Japan Clinical Oncology Group brain-tumor study group
Background: This study aimed to investigate what treatment are selected for malignant brain tumors, particularly glioblastoma (GBM) and primary central nervous system lymphoma (PCNSL), in real-world Japan and the costs involved. Methods: We conducted a questionnaire survey regarding treatment selections for newly diagnosed GBM and PCNSL treated between July 2021 and June 2022 among 47 institutions in the Japan Clinical Oncology Group-Brain Tumor Study Group. We calculated the total cost and cost per month of the initial therapy for newly diagnosed GBM or PCNSL. Results: The most used regimen (46.8%) for GBM in patients aged ≤74 years was ‘Surgery + radiotherapy concomitant with temozolomide’. This regimen’s total cost was 7.50 million JPY (Japanese yen). Adding carmustine wafer implantation (used in 15.0%), TTFields (used in 14.1%), and bevacizumab (BEV) (used in 14.5%) to the standard treatment of GBM increased the cost by 1.24 million JPY for initial treatment, and 1.44 and 0.22 million JPY per month, respectively. Regarding PCNSL, ‘Surgery (biopsy) + rituximab, methotrexate, procarbazine, and vincristine (R-MPV) therapy’ was the most used regimen (42.5%) for patients of all ages. This regimen incurred 1.07 million JPY per month. The three PCNSL regimens based on R-MPV therapy were in ultra-high-cost medical care (exceeding 1 million JPY per month). Conclusions: Treatment of malignant brain tumors is generally expensive, and cost-ineffective treatments such as BEV are frequently used. We believe that the results of this study can be used to design future economic health studies examining the cost-effectiveness of malignant brain tumors.
- 2 September 2024
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 54 (10) , 1123-1131
Open AccessCost of medical care for malignant brain tumors at hospitals in the Japan Clinical Oncology Group brain-tumor study group
Background: This study aimed to investigate what treatment are selected for malignant brain tumors, particularly glioblastoma (GBM) and primary central nervous system lymphoma (PCNSL), in real-world Japan and the costs involved. Methods: We conducted a questionnaire survey regarding treatment selections for newly diagnosed GBM and PCNSL treated between July 2021 and June 2022 among 47 institutions in the Japan Clinical Oncology Group-Brain Tumor Study Group. We calculated the total cost and cost per month of the initial therapy for newly diagnosed GBM or PCNSL. Results: The most used regimen (46.8%) for GBM in patients aged ≤74 years was ‘Surgery + radiotherapy concomitant with temozolomide’. This regimen’s total cost was 7.50 million JPY (Japanese yen). Adding carmustine wafer implantation (used in 15.0%), TTFields (used in 14.1%), and bevacizumab (BEV) (used in 14.5%) to the standard treatment of GBM increased the cost by 1.24 million JPY for initial treatment, and 1.44 and 0.22 million JPY per month, respectively. Regarding PCNSL, ‘Surgery (biopsy) + rituximab, methotrexate, procarbazine, and vincristine (R-MPV) therapy’ was the most used regimen (42.5%) for patients of all ages. This regimen incurred 1.07 million JPY per month. The three PCNSL regimens based on R-MPV therapy were in ultra-high-cost medical care (exceeding 1 million JPY per month). Conclusions: Treatment of malignant brain tumors is generally expensive, and cost-ineffective treatments such as BEV are frequently used. We believe that the results of this study can be used to design future economic health studies examining the cost-effectiveness of malignant brain tumors.
- Open Access
Predicting Impaired Cerebrovascular Reactivity and Hyperperfusion Syndrome with BeamSAT MRI in Carotid Artery Stenosis
Background We evaluated the impact of collateral flow of the middle cerebral artery (MCA) territory and cross flow visualized with internal carotid artery (ICA)-selective Magnetic resonance angiography (MRA) constructed by pencil beam presaturation (BeamSAT) pulse on preoperative cerebral hemodynamic status and postoperative hyperperfusion syndrome. Methods Fourty-eight patients who underwent carotid artery stenting or carotid endarterectomy were included. The preoperative status of collateral flow in the MCA territory and crossflow was assessed using ICA-selective MRA. Cerebral blood flow and cerebrovascular reactivity (CVR) were assessed using single-photon emission computed tomography. Potential signs of hyperperfusion syndrome (HPS) were retrospectively assessed by reviewing medical charts. Results Patients who either demonstrated mismatch in MCA signal intensity (MCA-MRA grade) between ICA-selective MRA by BeamSAT magnetic resonance imaging (MRI) and conventional MRA or whose MRA crossflow was visualized on BeamSAT MRI were placed in the developed collateral (DC) group (n=19). All other patients were placed in the undeveloped collateral (UC) group (n = 29). Preoperative ipsilateral CVR was significantly lower in the DC group than in the UC group (18.0±20.0% versus 48.3±19.5%; PConclusions The differences in the MCA-MRA grade and crossflow between ICA-selective and conventional MRA were associated with impaired CVR. BeamSAT MRI may be a valuable and non-invasive tool for assessing of cerebral hemodynamics and predicting postoperative HPS.
Open AccessPredicting Impaired Cerebrovascular Reactivity and Hyperperfusion Syndrome with BeamSAT MRI in Carotid Artery Stenosis
Background We evaluated the impact of collateral flow of the middle cerebral artery (MCA) territory and cross flow visualized with internal carotid artery (ICA)-selective Magnetic resonance angiography (MRA) constructed by pencil beam presaturation (BeamSAT) pulse on preoperative cerebral hemodynamic status and postoperative hyperperfusion syndrome. Methods Fourty-eight patients who underwent carotid artery stenting or carotid endarterectomy were included. The preoperative status of collateral flow in the MCA territory and crossflow was assessed using ICA-selective MRA. Cerebral blood flow and cerebrovascular reactivity (CVR) were assessed using single-photon emission computed tomography. Potential signs of hyperperfusion syndrome (HPS) were retrospectively assessed by reviewing medical charts. Results Patients who either demonstrated mismatch in MCA signal intensity (MCA-MRA grade) between ICA-selective MRA by BeamSAT magnetic resonance imaging (MRI) and conventional MRA or whose MRA crossflow was visualized on BeamSAT MRI were placed in the developed collateral (DC) group (n=19). All other patients were placed in the undeveloped collateral (UC) group (n = 29). Preoperative ipsilateral CVR was significantly lower in the DC group than in the UC group (18.0±20.0% versus 48.3±19.5%; PConclusions The differences in the MCA-MRA grade and crossflow between ICA-selective and conventional MRA were associated with impaired CVR. BeamSAT MRI may be a valuable and non-invasive tool for assessing of cerebral hemodynamics and predicting postoperative HPS.
- Open Access
- 8 December 2023
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 14, 417
Late intrathecal retraction of a lumboperitoneal shunt
Lumboperitoneal shunt placement is a good option for treating elderly patients with communicating normal pressure hydrocephalus (NPH) who are also on antiplatelet therapy following endovascular treatment of unruptured bilateral internal carotid artery aneurysms.
- 8 December 2023
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 14, 417
Open AccessLate intrathecal retraction of a lumboperitoneal shunt
Lumboperitoneal shunt placement is a good option for treating elderly patients with communicating normal pressure hydrocephalus (NPH) who are also on antiplatelet therapy following endovascular treatment of unruptured bilateral internal carotid artery aneurysms.
- Open Access
- 4 August 2023
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 14, 277
Combined transarterial and transvenous embolization of anterior cranial fossa dural arteriovenous fistula
Excessive glue injection into the drainage vein in patients with dural arteriovenous fistula (dAVF) can result in venous obstruction. We performed transarterial embolization (TAE) combined with transvenous embolization (TVE) with coils to prevent the glue from migrating into the normal cortical veins. A 57-year-old man was pointed out to have a Borden Type III anterior cranial fossa dAVF during a check-up for putaminal hemorrhage. Because a left frontal normal cortical vein drained into the pathological drainage vein, excessive glue injection into the drainage vein may have caused venous obstruction. We performed TVE with coils at the foot of the draining vein to prevent excessive migration of glue into the drainer, followed by TAE with glue. With this technique, complete obliteration of the shunt without venous ischemia was obtained. The combined treatment of TAE and TVE is effective in preventing venous ischemia caused by unintended migration of glue cast into the drainage vein.
- 4 August 2023
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 14, 277
Open AccessCombined transarterial and transvenous embolization of anterior cranial fossa dural arteriovenous fistula
Excessive glue injection into the drainage vein in patients with dural arteriovenous fistula (dAVF) can result in venous obstruction. We performed transarterial embolization (TAE) combined with transvenous embolization (TVE) with coils to prevent the glue from migrating into the normal cortical veins. A 57-year-old man was pointed out to have a Borden Type III anterior cranial fossa dAVF during a check-up for putaminal hemorrhage. Because a left frontal normal cortical vein drained into the pathological drainage vein, excessive glue injection into the drainage vein may have caused venous obstruction. We performed TVE with coils at the foot of the draining vein to prevent excessive migration of glue into the drainer, followed by TAE with glue. With this technique, complete obliteration of the shunt without venous ischemia was obtained. The combined treatment of TAE and TVE is effective in preventing venous ischemia caused by unintended migration of glue cast into the drainage vein.
- 14 July 2022
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 43 (8) , 1124-1130
Absence of the Anterior Communicating Artery on Selective MRA is Associated with New Ischemic Lesions on MRI after Carotid Revascularization
BACKGROUND AND PURPOSE: ICA-selective MRA using a pencil beam presaturation pulse can accurately visualize anterior communicating artery flow. We evaluated the impact of anterior communicating artery flow on the perioperative hemodynamic status and new ischemic lesions after carotid revascularization. MATERIALS AND METHODS: Eighty-three patients with carotid artery stenosis were included. We assessed anterior communicating artery flow using ICA-selective MRA. The preoperative hemodynamic status was measured using SPECT. We also measured the change in regional cerebral oxygen saturation after temporary ICA occlusion. New ischemic lesions were evaluated by DWI on the day after treatment. RESULTS: Anterior communicating artery flow was detected in 61 patients, but it was not detected in 22 patients. Preoperative cerebrovascular reactivity was significantly higher in patients with (versus without) anterior communicating artery flow with a mean peak systolic velocity of ≥200 cm/s (39.6% [SD, 23.8%] versus 25.2% [SD, 16.4%]; P = .030). The decrease in mean regional cerebral oxygen saturation was significantly greater in patients without (versus with) anterior communicating artery flow (8.5% [SD, 5.6%] versus 3.7% [SD, 3.8%]; P = .002). New ischemic lesions after the procedure were observed in 23 patients. The multivariate logistic regression analysis revealed that anterior communicating artery flow (OR, 0.07; 95% CI, 0.012–0.45; P = .005) was associated with new ischemic lesions. CONCLUSIONS: The absence of anterior communicating artery flow influenced the perioperative hemodynamic status in patients with carotid stenosis and was associated with an increased incidence of new ischemic lesions after carotid revascularization.
- 14 July 2022
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 43 (8) , 1124-1130
Absence of the Anterior Communicating Artery on Selective MRA is Associated with New Ischemic Lesions on MRI after Carotid Revascularization
BACKGROUND AND PURPOSE: ICA-selective MRA using a pencil beam presaturation pulse can accurately visualize anterior communicating artery flow. We evaluated the impact of anterior communicating artery flow on the perioperative hemodynamic status and new ischemic lesions after carotid revascularization. MATERIALS AND METHODS: Eighty-three patients with carotid artery stenosis were included. We assessed anterior communicating artery flow using ICA-selective MRA. The preoperative hemodynamic status was measured using SPECT. We also measured the change in regional cerebral oxygen saturation after temporary ICA occlusion. New ischemic lesions were evaluated by DWI on the day after treatment. RESULTS: Anterior communicating artery flow was detected in 61 patients, but it was not detected in 22 patients. Preoperative cerebrovascular reactivity was significantly higher in patients with (versus without) anterior communicating artery flow with a mean peak systolic velocity of ≥200 cm/s (39.6% [SD, 23.8%] versus 25.2% [SD, 16.4%]; P = .030). The decrease in mean regional cerebral oxygen saturation was significantly greater in patients without (versus with) anterior communicating artery flow (8.5% [SD, 5.6%] versus 3.7% [SD, 3.8%]; P = .002). New ischemic lesions after the procedure were observed in 23 patients. The multivariate logistic regression analysis revealed that anterior communicating artery flow (OR, 0.07; 95% CI, 0.012–0.45; P = .005) was associated with new ischemic lesions. CONCLUSIONS: The absence of anterior communicating artery flow influenced the perioperative hemodynamic status in patients with carotid stenosis and was associated with an increased incidence of new ischemic lesions after carotid revascularization.